Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Anthony R. Mato, MD

Anthony R. Mato, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Mato is a Penn Medicine employed physician.

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2008
  • Internal Medicine, 2005
  • Medical Oncology, 2008

Clinical Expertise:

  • Chronic Lymphocytic Leukemia (CLL)
  • Lymphoma

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: State University of New York at Buffalo
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American College of Physician Executives, National American Society of Clinical Oncology, National American Society of Hematology, National

Hospital Affiliation

Dr. Mato is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Selected Publications:

Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Sebastian Grosicki, Aleksander Pristupa, Ann Janssens, Jiri Mayer, Nancy L Bartlett, Marie-Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, Abraham Avigdor, Simon Rule, Diego Villa, Olga Samoilova, Panagiots Panagiotidis, Andre Goy, Anthony Mato, Miguel A Pavlovsky, Claes Karlsson, Michelle Mahler, Mariya Salman, Steven Sun, Charles Phelps, Sriram Balasubramanian, Angela Howes, Michael Hallek: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study The Lancet Oncology 17 (2): 200,2016.

Spencer Bachow, Chadi Nabhan, Anthony Mato, Christopher Flowers, Neil Kay, David Grinblatt, Matthew Davids, Mark Weiss, Kristen Sullivan, E Dawn Flick, Pavel Kiselev, Shriya Bhushan, Arlene Swern, Jeff Sharman, Nicole Lamanna: Characteristics and Outcomes in Women and Men in the Connect® CLL Registry Clinical lymphoma, leukemia and myeloma : 2016.

Prof Susan O'Brien, MD, Jeffrey A Jones, MD, Prof Steven E Coutre, MD, Anthony R Mato, MD, Prof Peter Hillmen, MBChB, Constantine Tam, MD, Prof Anders Österborg, MD, Tanya Siddiqi, MD, Michael J Thirman, MD, Richard R Furman, MD, Prof Osman Ilhan, MD, Prof Michael J Keating, MBBS, Timothy G Call, MD, Jennifer R Brown, MD, Michelle Stevens-Brogan, MSc, Yunfeng Li, PhD, Fong Clow, ScD, Danelle F James, MD, Alvina D Chu, MD, Prof Michael Hallek, MD, Prof Stephan Stilgenbauer, MD: Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study Lancet Oncology : 2016.

Emily C. Ayers, MD, Anthony Mato, MD1: Richter’s Transformation in the Era of Kinase Inhibitor Therapy: A Review Clinical Lymphoma Myeloma and Leukemia : 2016.

Jie Wang, Jennifer Morrissette, David B Lieberman, Colleen Timlin, Stephen Schuster, Anthony R Mato: Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations in Chronic Lymphocytic Leukemia British Journal of Hematology : 2016.

Anthony Mato, Chadi Nabhan, Neil E. Kay, Mark A. Weiss, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Ian W. Flinn, Mark F. Kozloff, Christopher R. Flowers, Charles M. Farber, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, E. Dawn Flick, and Jeff P. Sharman: Real-world clinical experience in the Connect® CLL registry: a prospective cohort study of 1494 patients across 199 US centres British Journal of Hematology : 2016.

Clinton Yam, Daniel J Landsburg, Kevin T Nead, Xinyi Lin, Anthony R Mato, Jakub Svoboda, Alison W Loren, Noelle V Frey, Edward A Stadtmauer, David L Porter, Stephen J Schuster, Sunita D Nasta: Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas American Journal Of Hematology : 2016.

Emily C Ayers, Sara Fardin, Saeid Gholami, Abass Alavi, Anthony R Mato: Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging PET Clinics : 2016.

Anthony R Mato, Chadi Nabhan, Paul M. Barr, Chaitra S Ujjani, Brian Hill, Nicole Lamanna, Alan Skarbnik, Christina M Howlett, Jeffrey J Pu, Alison Sehgal, Lauren Strelec, Alexandra M Vandegrift, Danielle M Fitzpatrick, Clive S Zent, Tatyana Feldman, Andre H Goy, David Claxton, Spencer H Bachow, Gurbakhash Kaur, Jakub Svoboda, Sunita D Nasta, Daniel Landsburg, Stephen Schuster, David L Porter, Bruce D. Cheson, Pavel Kiselev, and Andrew M Evens: Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience BLOOD : 2016.

Andrzej Hellman, Janusz Kloczko, Javier Loscertales, Ewa Lech- Maranda, John M. Pagel, Anthony Mato, John C. Byrd, Farrukh T Awan, Holger Hebart,Jose A Garcia-Marco, Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott C. Stromatt and Ulrich Jaeger: Randomized Phase 2 Study of Otlertuzumab and Bendamustine vs Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia British Journal of Hematology : 2016.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-160
3400 Civic Center Blvd

Philadelphia, PA 19146
Phone: (215) 615-7361
Fax: (215) 615-5888
Patient appointments: 800-789-PENN (7366)

Related Links